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Abstract
Background: The molecular mechanisms by which iron is physiologically transported trough the
cellular membranes are still only partially understood. Several studies indicate that a reduction step
of ferric iron to ferrous is necessary, both in the case of transferrin-mediated and transferrin-
independent iron uptake. Recent studies from our laboratory described gamma-
glutamyltransferase activity (GGT) as a factor capable to effect iron reduction in the cell
microenvironment. GGT is located on the outer aspect of plasma membrane of most cell types,
and is often expressed at high levels in malignant tumors and their metastases. The present study
was aimed at verifying the possibility that GGT-mediated iron reduction may participate in the
process of cellular iron uptake.
Results: Four distinct human tumor cell lines, exhibiting different levels of GGT activity, were
studied. The uptake of transferrin-bound iron was investigated by using 55Fe-loaded transferrin, as
well as by monitoring fluorimetrically the intracellular iron levels in calcein-preloaded cells.
Transferrin-independent iron uptake was investigated using 55Fe complexed by nitrilotriacetic acid
(55Fe-NTA complex).
The stimulation of GGT activity, by administration to cells of the substrates glutathione and glycyl-
glycine, was generally reflected in a facilitation of transferrin-bound iron uptake. The extent of such
facilitation was correlated with the intrinsic levels of the enzyme present in each cell line.
Accordingly, inhibition of GGT activity by means of two independent inhibitors, acivicin and serine/
boric acid complex, resulted in a decreased uptake of transferrin-bound iron. With Fe-NTA
complex, the inhibitory effect – but not the stimulatory one – was also observed.
Conclusion: It is concluded that membrane GGT can represent a facilitating factor in iron uptake
by GGT-expressing cancer cells, thus providing them with a selective growth advantage over clones
that do not possess the enzyme.
Background
Iron is involved in several primary cellular functions –
such as DNA synthesis, ATP generation, electron transfers,
oxidation of substrates – and is therefore an essential
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factor for cell survival and replication [reviewed in [1]].
On the other hand, iron may also catalyze oxidation-re-
duction (redox) reactions, leading to the production of
free radicals and potentially noxious oxidative stress. As a
consequence, living organisms developed strictly regulat-
ed processes for iron transport, uptake and storage, and a
balance between these mechanisms is essential for life [2].
In aqueous, non-acidic environments, iron exists in high-
ly insoluble polymeric forms. Consequently, cells had to
devise specific strategies to solubilize and absorb the met-
al. These include i) systems capable to effect the reduction
of ferric ions to the more soluble ferrous form, and ii) the
use of proteins capable to transport ferric iron as such,
such as e.g. transferrins [3]. The main pathway for iron up-
take by animal cells is through the plasmatic protein iron
carrier, transferrin (Tf), and its specific receptor (TfR) lo-
cated at the cell surface. Following the ligand binding, the
Tf/TfR complex is internalized by a receptor-mediated en-
docytosis and iron is released by a process involving endo-
somal acidification through an influx of protons through
an ATP-dependent proton pump [4,5]. Other studies have
suggested that another critical step in cellular uptake of Tf-
bound iron may be the reduction of ferric iron to ferrous
[6], and several molecular species acting as reductants
have been described, including the superoxide anion,
ascorbic acid and thiol compounds [7]. However, the role
of these processes in iron uptake from Tf remains contro-
versial and still subject to debate. As recently pointed out
by Kwok et al.[8], lines of evidence suggest that Fe3+ re-
duction takes place after uptake, as Fe is released from en-
dosomes into the cytosol.
Besides Tf-bound iron, animal cells can also obtain iron
from small, non-protein, low molecular weight complex-
es. Such complexes can originate in conditions such as
iron overload when the binding capacity of transferrin is
saturated and free, "non-Tf-bound iron" (NTBI) is gener-
ated [9]. Interestingly, the involvement of free radical re-
actions in the uptake of NTBI has also been recently
proposed [10].
Altogether, the precise molecular mechanisms by which
iron is physiologically unloaded from its complexes and
transported trough the cellular membranes in eukariotic
cells are still in need of elucidation. With respect to the
possibility that a reduction of Fe3+ to Fe2+ may represent
a critical step in the process, thiol (-SH) compounds are
known to reduce iron efficiently [11]. Such iron-reducing
ability can be demonstrated for several molecules, includ-
ing the well-known antioxidant tripeptide glutathione
(gamma-glu-cys-gly; GSH) [12]. GSH – one of the main
cellular antioxidants – as such cannot cross plasma mem-
brane of most cell types, and thus the recovery of extracel-
lular GSH is warranted by membrane gamma-glutamyl
transpeptidase (GGT), an ecto-enzyme with the active site
oriented toward the outer cell surface. GGT is capable to
start the catabolism of extracellular GSH, and as in most
cell types a continuous efflux of GSH to the extracellular
space exists, in cells expressing GGT at their surface a con-
tinuous "GSH cycling" across the plasma membrane
therefore occurs [13]. Recent studies of our and other lab-
oratories have highlighted the role that GGT activity can
play in the redox regulation of cellular functions, isofar as
the GGT-mediated cleavage of GSH gives rise to the thiol
dipeptide cysteinyl-glycine, whose -SH group is much
more reactive than the one of GSH [14], and is provided
in particular with a much stronger iron-reducing ability
[15,11].
Against this background, the present study was aimed to
investigate if GGT activity could represent a mechanism
for the reduction of iron, capable to interfere favourably
with its uptake by the cell. GGT activity is elevated in a
number of human primary as well as metastatic tumors,
such as e.g. ovary [16], colon [17], lung [18], liver [19],
prostate [20], sarcoma [21], melanoma [22], leukemias
[23], especially in their metastatic forms. In a series of 60
different human tumor cell lines, GGT was significantly
expressed in 70% of cases [24]. GGT-mediated iron reduc-
tion may thus represent a widespread characteristic of ma-
lignant cells. It is well established that the generally higher
iron uptake by cancer cells is often the result of a higher
number of transferrin receptors [8]. The iron-reducing ef-
fect of membrane GGT activity may play an additional
role in iron supply of malignant cells, thus contributing to
support the role of iron in carcinogenesis which a number
of studies has highlighted [reviewed in [25]].
Results
Figure 1 shows the results of 55Fe-Tf uptake in the differ-
ent neoplastic cell lines studied. In U937 cells (Fig. 1A),
GGT stimulation with the substrates GSH and glycyl-gly-
cine significantly increased Tf-mediated 55Fe uptake. A
small but significant increase in iron uptake was also ob-
served in cells treated with glycyl-glycine alone. Converse-
ly, in cells pretreated with the irreversible, non-
competitive inhibitor acivicin, a significant decrease in
55Fe uptake was observed, both in control cells and in
cells stimulated with GSH and glycyl-glycine. As a confir-
mation of the inhibitory effect of acivicin, the same effect
was observed in cells after GGT inhibition by the structur-
ally independent, competitive inhibitor SBC. Efficacy and
specificity of GGT inhibition by acivicin and by SBC was
thoroughly assessed in earlier studies by A. Meister's
group [26,27]. A similar pattern of response was observed
in GGT-rich Me665/2/60 cells (Fig. 1B). Again, GGT stim-
ulation significantly increased Tf-mediated 55Fe uptake,
and a small effect of glycyl-glycine alone was also present.
GGT inhibition experiments resulted in significantCancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/7
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inhibition of iron uptake in the case of SBC treatment. In
K562 cells (Fig. 1C) expressing a lower GGT activity, an in-
significant increase in 55Fe-Tf uptake was observed after
GGT stimulation. On the other hand, GGT inhibition
with acivicin resulted in inhibition of iron uptake, which
was significant in the case of GGT stimulated cells. In
Me665/2/21 cells, possessing only traces of GGT activity,
no significant effects of GGT modulation on iron uptake
was observed (Fig. 1D). A plot of cellular GGT activity lev-
els against the corresponding extents of increase in Tf-iron
uptake observed in each cell line after GGT stimulation is
reported in Fig. 2. A significant logarithmic correlation
was present between the two sets of values.
The observed facilitating effects of GGT activity on 55Fe-Tf
uptake was verified with K562 cells in different
Figure 1
Effects of modulation of membrane GGT activity on transferrin-mediated uptake of 55Fe by 4 human cancer 
cell lines expressing different levels of GGT activity. Data shown are means ± SEM of 2–5 experiments. Panel A: U937 
histiocytoma cells (*significantly different from control value, P < 0.05; **significantly different from the "+GSH+gly-gly" value, P 
< 0.05). Panel B: Me665/2/60 melanoma cells (*significantly different from control value, P < 0.05). Panel C: K562 erythroleuke-
mia cells (**significantly different from the "+GSH+gly-gly" value, P < 0.05). Panel D: Me665/2/21 melanoma cells (differences 
not statistically significant).Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/7
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experimental conditions, by analyzing the iron-induced
quenching of intracellular fluorescence of calcein-
preloaded cells. Fluorescence decrease induced by admin-
istration of iron-loaded transferrin was largely prevented
in cells whose GGT activity had been irreversibly inhibited
by acivicin (Fig. 3). On the other hand the stimulation of
GGT activity with this methodology did not result in ap-
preciable stimulation of Tf uptake, suggesting that GGT-
dependent Fe uptake may already be maximal in these
cells.
Experiments with Fe-NTA were carried out with the two
cell lines with higher GGT activity, U937 and Me665/2/60
cells. As can be seen in Fig. 4, no significant effect of GGT
stimulation was observed, while GGT inhibition with the
competitive inhibitor SBC did produce a significant inhi-
bition of non-Tf-bound iron uptake in both lines.
Discussion
The results of the present study suggest that GGT activity
expressed by tumor cells may play a positive role in the
uptake of transferrin-bound iron. In fact, in U937 and
Me665/2/60 cells, exhibiting medium-high levels of GGT
activity, stimulation of the enzyme significantly increased
Tf-mediated 55Fe uptake. Accordingly, two independent
inhibitors of GGT activity, the irreversible non-competi-
tive one acivicin, as well as the specific competitive one
serine/boric acid complex – caused a significant decrease
in  55Fe-Tf uptake. This effect is likely to be mediated
through the known ability of GGT activity to promote re-
dox reactions, including iron reduction according to the
following sequence [28,14]:
GSH + gly-gly ---(GGT)---> gamma-glu-gly-gly + gly-cys-S-
+ H+   <1>
gly-cys-S- + Fe3+ ----------> gly-cys-S. + Fe2+   <2>
The -SH group of the dipeptide cysteinyl-glycine in fact is
much more reactive than the one of GSH [14], and is pro-
vided in particular with a much stronger iron-reducing
ability [15,11]. Interestingly, the fact that the inhibitory
effects of acivicin and SBC were observed both in GGT-
stimulated and in control cells indicates that GGT activity
is capable to effect a facilitation of 55Fe-Tf uptake even in
basal, unstimulated conditions. Indeed, previous work
has documented that U937 [29] and Me665/2/60 cells
[30], like many other cell types, present with a continuous
efflux of GSH, which is continuously recovered by cells
through its extracellular catabolism by membrane GGT
activity. The fact that stimulation of GGT by glycyl-glycine
alone also induced a significant stimulation of iron up-
Figure 2
Correlation between membrane GGT activity of 4 
human tumor cell lines and the corresponding GGT-
stimulatable uptake of transferrin-bound iron. Data 
shown are means ± SEM of 3–5 experiments. The logarithmic 
correlation curve shown is statistically significant (r = 0.99).
Figure 3
Effects of GGT inhibition on transferrin-bound iron 
uptake in K562 cells. Online fluorimetric monitoring of 
intracellular iron levels. Transferrin (>70% iron-saturated) 
was added where indicated, and the decrease in fluorescence 
of intracellular calcein was recorded (cfr. Methods for details 
of the procedure). One representative experiment out of 
five is reported.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/7
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take indeed confirms that sufficient GSH was available to
GGT activity, even in absence of exogenous addition.
Thus, GGT activity appears capable to facilitate 55Fe-Tf up-
take even under basal conditions.
The lack of effect of GGT stimulation in Me665/2/21 cells
– possessing only traces of GGT activity – actually pro-
vides sort of a 'negative control' for the phenomenon. In
K562 cells, possessing low GGT levels, the facilitation ef-
fect of GGT stimulation on 55Fe-Tf uptake was not signif-
icant; however pretreatment with GGT inhibitor acivicin
prior to addition of GGT substrates reduced Fe uptake sig-
nificantly. A facilitating role of GGT in K562 cells could
also be demonstrated by means of an alternative method-
ology, i.e. fluorimetric determination of intracellular iron
levels (Fig. 3). In these experiments, the mere inhibition
of GGT resulted in a marked inhibition of Tf-iron uptake,
again pointing to a role of basal GGT activity in iron
uptake.
Altogether, the data obtained with the three GGT-positive
tumor cell lines indicate that a facilitation effect is already
present at relatively low levels of GGT activity (5–10 mU/
mg protein), while much higher GGT levels, such as those
in Me665/2/60 cells, do not correspond to comparably
higher facilitating effects (Fig. 2).
With respect to non-Tf-bound uptake, GGT stimulation
did not appear to produce any significant effects, at least
in the two lines tested (U937 and Me665/2/60 cells),
while a marked inhibition of iron uptake was observed in
both lines following GGT inhibition by SBC. This finding
suggests that a facilitatory role of GGT on non-Tf-bound
iron uptake exists, but is already maximal under condi-
tions of basal GGT activity, and cannot be further
stimulated.
Conclusions
The findings suggest that membrane GGT activity can ex-
ert a facilitating effect on iron uptake, potentially repre-
senting an additional mechanism for iron supply in
cancer cells presenting with up-regulated levels of this en-
zyme. This effect is probably mediated through redox in-
teractions of GGT-derived reactive thiols and/or
prooxidant species, although further studies are needed to
determine the precise mechanism(s) involved.
Studies of experimental carcinogenesis evidenced GGT ex-
pression as a marker of tumor progression [31,32], and –
Figure 4
Effects of modulation of membrane GGT activity on the uptake of 55Fe-nitrilotriacetate complex by GGT-rich 
U937 (A) and Me665/2/60 cells (B). Data shown are means ± SEM of 3–5 experiments. * Significantly different from con-
trol value, P < 0.05.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/7
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as mentioned above – a number of human malignancies
express GGT at medium-high levels. Iron is an important
nutrient for actively proliferating neoplastic cells. As the
expression of GGT is highly inhomogeneous among cell
clones belonging to the same tumor [20,33], it is conceiv-
able that the additional gain in iron uptake allowed by
GGT – although of limited extent – may confer GGT-rich
clones with a growth advantage over GGT-poor ones, thus
helping to explain the higher levels of GGT usually detect-
able in late stage and metastatic malignancies.
Methods
Cell cultures and incubations
Four human tumor cell lines, displaying different mem-
brane GGT activities, were used. GGT activity was assayed
with the method of Sze et al. [34], involving the spectro-
photometric measurement of p-nitroaniline released
from the substrate gamma-glutamyl p-nitroanilide (GP-
NA). One unit of GGT activity was defined as the amount
of the enzyme capable to release 1 µmol p-nitroanilide/
min from the substrate GPNA [35]. U937 histiocytoma
cells and Me665/2/60 melanoma cells were provided with
medium-high GGT activity (≅15 and ≅65 mU GGT/mg
protein, respectively), while GGT levels were lower (≅8
mU/mg protein) in K562 erythroleukemia cells, and virtu-
ally absent (≅0.2 mU/mg protein) in Me665/2/21
melanoma cells. All lines were routinely cultured in RPMI
1640 medium, containing 10% heat-inactivated fetal calf
serum (FCS), 2 mM L-glutamine, 0.25 µg/ml amphoter-
icin B and 50 µg/ml gentamycin), at 37°C, under 95% air
: 5 % CO2 in a humidified atmosphere.
Modulation of GGT activity
For stimulation of cellular GGT activity, cell lines were in-
cubated in the presence of the substrate, GSH (200 µM),
and the co-substrate glycyl-glycine (2 mM) serving as the
acceptor of gamma-glutamyl moieties for the transpepti-
dation reaction [35]. Inhibition of GGT was obtained by
exposing cells to the non-competitive inhibitor acivicin
(130 µM), for 4 h prior to experiments, or alternatively, by
performing experiments in the presence of the specific
competitive inhibitor serine/boric acid complex (SBC),
10/10 mM [27].
Preparation of 55Fe-Tf
The procedure of Klausner et al. [36], with slight modifi-
cations, was used. 55FeCl3, 0.4 mCi (NEN Life Sci. Prod-
ucts, Boston, USA), was complexed to nitrilo-triacetic acid
(NTA; Sigma, S.Louis, USA) at a ratio of 0.18 µmol Fe : 1.8
µmol NTA, followed by the addition of 0.045 µmol of hu-
man apo-transferrin (Sigma) dissolved in 1 M Tris-HCl, 2
mM NaHCO3 buffer, pH 8.5. 55Fe-Tf was separated from
non-bound  55Fe by gel-filtration on a PD-10 column
(Amersham Biosciences, Italy) pre-equilibrated with
buffer.
Measurement of 55Fe-Tf cellular uptake
U937 and K562 cells were seeded at 2 × 105 /ml, while
Me665/2/60 and Me665/2/21 cells were seeded at 2 ×
104/cm2. After 24 h, cells were incubated in RPMI con-
taining BSA 0.1%, at 37°C for 45 min, in order to allow
the detachment of bovine Tf contained in FCS [37]. After
changing the medium with fresh RPMI/BSA 0.1%, 4 µl/ml
of the 55Fe-Tf solution were added to cell cultures and the
incubations were prolonged at 37°C for 2.5 h. Control
samples were mantained at 4°C, i.e. in conditions that
prevent cells to absorb the metal, or alternatively 55Fe-Tf
was added immediately before washes (t 0); the latter
samples indicated the aspecific binding of radioactivity to
cells, and their values were substracted from the results. At
the end of the incubations, samples were washed 3 times
with Hepes-buffered saline (pH 7.4), resuspended in 200
µl, and counted in a scintillation beta-counter (Canberra
Packard, Australia).
Measurement of non-Tf-bound iron uptake
Further experiments were carried out with the low molec-
ular weight complex, iron nitrilo-triacetate (Fe-NTA). To
cells pre-treated for either GGT stimulation or inhibition,
a loading solution (400 mM NTA plus 100 mM FeCl3,
containing 1% (vol/vol) of a stock 55FeCl3 solution (107
cpm/ml) was added, and incubations were prolonged for
45 min at 37°C (or at 4°C = controls for non-specific 55Fe
absorption). At the end of incubations, cells were washed
3 times in ice-cold Hepes-buffered saline, resuspended in
200 µl of 5% trichloracetic acid and left on ice for 20 min.
After centrifugation (17,000 g, 15 min), aliquots of the su-
pernatants were withdrawn and counted in the scintilla-
tion beta-counter.
Measurement of intracellular iron levels by means of cal-
cein fluorescence
The method of Cabantchik et al. [38] was used. Briefly,
K562 cells (1 × 106/ml) were pre-incubated with 0.25 µM
calcein acetoxymethyl ester (CAM; Molecular Probes, Eu-
gene, USA) in serum-free MEM medium containing 1 mg/
ml BSA and 20 mM Hepes (pH 7.3), washed of excess
CAM and resuspended in fresh medium. For determina-
tions, aliquots of cell suspensions were transferred to a
stirred, thermostatted cuvette, transferrin (>70% iron-sat-
urated; Kama-Da Industries, Israel) was added (100 µg/
ml), and fluorescence was monitored at an excitation of
488 nm and an emission of 517 nm using a PTI fluores-
cence station (PTI, South Brunswick, USA).
Statistics
Statistic evaluation of data was performed by means of
ANOVA test, and results with probability P < 0.05 were
considered as significant.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/7
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